Oxford claims Covid-19 vaccine is safe and induces immunity

Researchers from the University of Oxford in England, published on Monday (20/7), in the scientific journal The Lancet, the results of the first phase of human trials of the vaccine developed in partnership with the biopharmaceutical AstraZeneca. The vaccine proved to be safe and capable of inducing immune response to volunteers.
The vaccine is one of the most advanced stage in the world. It is currently in phase 3, with tests with 8,000 volunteers in the UK and another 2,000 in Brazil and 2,000 in South Africa. This is the last step before immunization passes into the regulatory and manufacturing process if it presents favorable results.
Between April 23 and May 21, 2020, 1,077 healthy people with no history of infection with the new coronavirus participated in the experiment. According to scientists, the vaccine showed an acceptable safety profile, with production of antibodies and T cells against the new coronavirus.
Neutralizing antibody responses against Sars-CoV-2 were detected in 91% of participants after a single dose. After the booster dose, all participants had neutralizing activity.
T cells peaked on the 14th day after application. IgG responses, also called memory antibody, increased on day 28 and were increased after a second dose.
"These results, along with the induction of humoral and cellular immune responses, support the large-scale evaluation of this candidate vaccine in an ongoing phase 3 program," the study says.
The most common local and systemic reactions were local pain, fever, chills, muscle pain, headache, and malaise. No serious adverse events have been reported.